Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ProShares Ultra Silver ETF (AGQ) vs Novartis AG (NVS) Price & Performance

ProShares Ultra Silver ETFTrade
Novartis AGTrade

Price performance (Past 24H)

Key statistics

ProShares Ultra Silver ETF vs Novartis AG — how do they compare? ProShares Ultra Silver ETF trades at $81.98, while Novartis AG trades at $152.94 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while ProShares Ultra Silver ETF pays none, and Novartis AG is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.

AGQNVS
Sector
Leveraged / InverseHealth
52-Week High
$400.47$168.62
52-Week Low
$49.73$119.31
Market Cap
$295.37B
Enterprise Value
$336.69B
Dividend Yield
3.07%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ProShares Ultra Silver ETF

AGQ, the ProShares Ultra Silver ETF, trades at $83.06, up 1.44% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent news highlights its volatility, surging 9.39% on silver rallies but facing structural decay concerns due to 2x daily leverage. Financial ratios are unavailable as it is an ETF tracking silver futures.

Outlook is highly speculative, offering amplified silver exposure with significant risk. Opportunities exist if silver prices rise, but risks include leverage decay, volatility-driven losses, and silver market downturns. Investors should weigh aggressive gains against potential rapid declines.

Novartis AG

Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.

The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ProShares Ultra Silver ETF

AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.

Read more on AGQ

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Read more on NVS